Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2612149 | 1.00 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL303956 | 1.00 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL1644095 | 0.98 | CTSK (0.48) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL1644093 | 0.98 | CTSK (0.48) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL205184 | 0.90 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1487792 | 0.90 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL205183 | 0.90 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL28031453 | 0.89 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL2191093 | 0.89 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL376450 | 0.89 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118389633-A | Method for monitoring glutamine uptake of tumor cells in real time and application | 杭州师范大学 | 2024-07-26 | — | — | CN | claimed |
| CN-114213503-A | Synthesis method of snake venom-like tripeptide | 上海予利生物科技股份有限公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3560932-B1 | PROCESS FOR PREPARING 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES OF SAME | JAPAN TOBACCO INC (JP) | 2026-03-11 | — | — | EP | disclosed |
| WO-2026043829-A1 | CHROMANE CYCLIC AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025262460-A1 | LIPID COMPOSITIONS FOR NUCLEIC ACID DELIVERY | BioNTech SE (DE) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262672-A1 | LIPID COMPOSITIONS FOR NUCLEIC ACID DELIVERY | BioNTech SE (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4651905-A1 | NOVEL LINKERS FOR SUSTAINED DELIVERY OF THERAPEUTICS | Eli Lilly and Company (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250205348-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-06-26 | — | — | US | disclosed |
| CN-120202243-A | Thermosetting resin composition, cured film, substrate, and electronic component | 捷恩智株式会社 | 2025-06-24 | — | — | CN | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| US-6215002-B1 | CYCLIZATION, DEBLOCKING, DEPROTECTION, SULFONATION, CONDENSATION, AMIDATION; ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS | GLAXO WELLCOME INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1019386-A1 | REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-07-19 | — | — | EP | disclosed |
| US-6057457-A | ENZYME INHIBITORS FOR PROTEASE OR ENZYMES OF HYDROLYSIS | GLAXO WELLCOME INC. (US) | 2000-05-02 | — | — | US | disclosed |
| US-5994344-A | BRONCHITIS THERAPY | GLAXO WELLCOME INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1998038179-A1 | REVERSE HYDROXAMATE DERIVATIVES AS METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
| US-5610141-A | CELL DIVISION STIMULANT | NYCOMED IMAGING AS (NO) | 1997-03-11 | — | — | US | disclosed |
| EP-0673388-A1 | DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-09-27 | — | — | EP | disclosed |
| WO-1993024523-A1 | DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | HAFSLUND NYCOMED AS (NO) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | CTSK 3595/4885CTSS 4282/4885MEN1 474/4885 |
| US-20250205348-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | RPN1, CLSPN, FRG1 | CTSK 3059/4885CTSS 2762/4885MEN1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.